BNP PARIBAS ARBITRAGE/CALL/ELI LILLY & CO/800/0.01/20.12.24 | Real-time Borsa Italiana 09:22:05 2024-07-04 am EDT | ||
| 1.44 EUR | +0.49% |
|
| Current month | -2.52% | ||
| 1 month | +44.31% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
| Date | Price | Change |
|---|---|---|
| 24-07-04 | 1.44 | +0.49% |
| 24-07-03 | 1.433 | -2.38% |
| 24-07-02 | 1.468 | -3.42% |
| 24-07-01 | 1.52 | +3.40% |
| 24-06-28 | 1.47 | -1.01% |
Real-time Borsa Italiana
Last update July 04, 2024 at 09:22 am EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
BNP Paribas
|
| P22T98 | |
| ISIN | NLBNPIT22T98 |
| Date issued | 2024-05-08 |
| Strike | 800 $ |
| Maturity | 2024-12-20 (169 Days) |
| Parity | 100 : 1 |
| Emission price | - € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.615 € |
|---|---|
| Lowest since issue | 0.598 € |
| Spread | 0.244 € |
| Spread % | 15.64% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
898.1
USD
Average target price
870.3
USD
Spread / Average Target
-3.10%
- Stock Market
- Warrants
- P22T98 Warrant
